Artelo Biosciences Q3 net loss widens to $3.1 mln

Artelo Biosciences

12/11/2025 13:11

Overview

Artelo Biosciences reports Q3 net loss of $3.1 mln, increased R&D and G&A expenses

Positive interim Phase 2 data for ART27.13 attracts partnering interest

Company completed public offering of common stock for $3.0 mln

Outlook

Company expects first-in-human study for ART12.11 to start in 1H 2026

Artelo sees partnering interest for ART27.13 following positive Phase 2 data

Company finalizing protocol for ART26.12 multiple ascending dose study

Result Drivers

R&D - Research and development expenses were $1.3 million for the quarter ended September 30, 2025, compared to $0.3 million for the same period in 2024, during which $1.3 million of UK tax credits were received

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$3.10 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Press Release: ID:nGNX7PzSN7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)